IL-10 enhances MD-2 and CD14 expression in monocytes and the proteins are increased and correlated in HIV-infected patients

Journal of Immunology

Volumn 182, Issue 1, 2009, Pages 588-595

  Sandanger, Øystein ^a   Ryan, Liv ^a   Bohnhorst, Janne ^a   Iversen, Ann Charlotte ^a   Husebye, Harald ^a   Halaas, Øyvind ^a   Landrø, Linn ^b   Aukrust, Pål ^b   Frøland, Stig S ^b   Elson, Greg ^c   Visintin, Alberto ^d   Øktedalen, Olav ^e   Damås, Jan Kristian ^a   Sundan, Anders ^a   Golenbock, Douglas ^d   Espevik, Terje ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c Nov Immune SA   (Switzerland)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD15 ANTIGEN; CD19 ANTIBODY; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IIC1; PROTEIN MD 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; AUTACOID; DIAGNOSTIC AGENT; LY96 PROTEIN, HUMAN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOCYTOSIS; ENDOSOME; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MONOCYTE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; ADULT; ANIMAL; ANTIBODY COMBINING SITE; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; CELL LINE; CHO CELL; CRICETULUS; GENETICS; HAMSTER; IMMUNOLOGY; METABOLISM; MOUSE; PHYSIOLOGY; UPREGULATION;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD14; BINDING SITES, ANTIBODY; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; HIV INFECTIONS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-10; LYMPHOCYTE ANTIGEN 96; MALE; MICE; MICE, INBRED BALB C; MONOCYTES; RNA, MESSENGER; UP-REGULATION;

EID: 59849095341     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.182.1.588     Document Type: Article

References (43)

1. Uematsu, S., and S. Akira. 2007. Toll-like receptors and Type I interferons. J. Biol. Chem. 282: 15319-15323.
2. Husebye, H., O. Halaas, H. Stenmark, G. Tunheim, O. Sandanger, B. Bogen, A. Brech, E. Latz, and T. Espevik. 2006. Endocytic pathways regulate Toll-like receptor 4 signaling and link innate and adaptive immunity. EMBO J. 25: 683-692.
3. Lien, E., P. Aukrust, A. Sundan, F. Muller, S. S. Froland, and T. Espevik. 1998. Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events. Blood 92: 2084-2092.
4. Frey, E. A., D. S. Miller, T. G. Jahr, A. Sundan, V. Bazil, T. Espevik, B. B. Finlay, and S. D. Wright. 1992. Soluble CD14 participates in the response of cells to lipopolysaccharide. J. Exp. Med. 176: 1665-1671.
5. Latz, E., A. Visintin, E. Lien, K. A. Fitzgerald, B. G. Monks, E. A. Kurt-Jones, D. T. Golenbock, and T. Espevik. 2002. Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. J. Biol. Chem. 277: 47834-47843.
6. da Silva, C. J., and R. J. Ulevitch. 2002. MD-2 and TLR4 N-linked glycosylations are important for a functional lipopolysaccharide receptor. J. Biol. Chem. 277: 1845-1854.
7. Ohto, U., K. Fukase, K. Miyake, and Y. Satow. 2007. Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science 316: 1632-1634.
8. Kim, H. M., B. S. Park, J. I. Kim, S. E. Kim, J. Lee, S. C. Oh, P. Enkhbayar, N. Matsushima, H. Lee, O. J. Yoo, and J. O. Lee. 2007. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130: 906-917.
9. Jain, V., A. Halle, K. A. Halmen, E. Lien, M. Charrel-Dennis, S. Ram, D. T. Golenbock, and A. Visintin. 2008. Phagocytosis and intracellular killing of MD-2 opsonized gram-negative bacteria depend on TLR4 signaling. Blood 111: 4637-4645.
10. Tissieres, P., I. Dunn-Siegrist, M. Schappi, G. Elson, R. Comte, V. Nobre, and J. Pugin. 2008. Soluble MD-2 is an acute-phase protein and an opsonin for Gram-negative bacteria. Blood 111: 2122-2131.
11. Nagai, Y., S. Akashi, M. Nagafuku, M. Ogata, Y. Iwakura, S. Akira, T. Kitamura, A. Kosugi, M. Kimoto, and K. Miyake. 2002. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat. Immunol. 3: 667-672.
12. Endo, S., K. Inada, T. Kasai, T. Takakuwa, H. Nakae, M. Kikuchi, H. Yamashita, and M. Yoshida. 1994. Soluble CD14 (sCD14) levels in patients with multiple organ failure (MOF). Res. Commun. Chem. Pathol. Pharmacol. 84: 17-25.
13. Landmann, R., W. Zimmerli, S. Sansano, S. Link, A. Hahn, M. P. Glauser, and T. Calandra. 1995. Increased circulating soluble CD14 is associated with high mortality in gram-negative septic shock. J. Infect. Dis. 171: 639-644.
14. Pugin, J., S. Stern-Voeffray, B. Daubeuf, M. A. Matthay, G. Elson, and I. Dunn-Siegrist. 2004. Soluble MD-2 activity in plasma from patients with severe sepsis and septic shock. Blood 104: 4071-4079.
15. Tissieres, P., I. Dunn-Siegrist, M. Schappi, G. Elson, R. Comte, V. Nobre, and J. Pugin. 2007. Soluble MD-2 is an acute phase protein and an opsonin for Gram-negative bacteria. Blood 111: 2122-2131.
16. Espevik, T. 1985. Human monocyte-mediated lysis of antibody-coated tumor cells: the role of the cytoskeleton in monocytes. J. Immunol. 134: 2017-2025.
17. Espevik, T., M. Otterlei, G. Skjak-Braek, L. Ryan, S. D. Wright, and A. Sundan. 1993. The involvement of CD14 in stimulation of cytokine production by uronic acid polymers. Eur. J. Immunol. 23: 255-261.
18. Jain, V., A. Halle, K. A. Halmen, E. Lien, M. Charrel-Dennis, S. Ram, D. T. Golenbock, and A. Visintin. 2008. Phagocytosis and intracellular killing of MD-2 opsonized Gram-negative bacteria depend on TLR4 signaling. Blood 111: 4637-4645.
19. Viriyakosol, S., P. B. McCray, M. E. Ashbaugh, J. Chu, H. P. Jia, J. Weiss, and T. N. Kirkland. 2006. Characterization of monoclonal antibodies to human soluble MD-2 protein. Hybridoma 25: 349-357.
20. Bernasconi, N. L., N. Onai, and A. Lanzavecchia. 2003. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 101: 4500-4504.
21. Kagan, J. C., T. Su, T. Horng, A. Chow, S. Akira, and R. Medzhitov. 2008. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat. Immunol. 9: 361-368.
22. Tanimura, N., S. Saitoh, F. Matsumoto, S. Akashi-Takamura, and K. Miyake. 2008. Roles for LPS-dependent interaction and relocation of TLR4 and TRAM in TRIF-signaling. Biochem. Biophys. Res. Commun. 368: 94-99.
23. Ohnishi, T., M. Muroi, and K. Tanamoto. 2003. MD-2 is necessary for the tolllike receptor 4 protein to undergo glycosylation essential for its translocation to the cell surface. Clin. Diagn. Lab. Immunol. 10: 405-410.
24. Muller, F., P. Aukrust, E. Lien, C. J. Haug, and S. S. Froland. 1998. Enhanced interleukin-10 production in response to Mycobacterium avium products in mononuclear cells from patients with human immunodeficiency virus infection. J. Infect. Dis. 177: 586-594.
25. Visintin, A., K. A. Halmen, E. Latz, B. G. Monks, and D. T. Golenbock. 2005. Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2. J. Immunol. 175: 6465-6472.
26. Divanovic, S., A. Trompette, S. F. Atabani, R. Madan, D. T. Golenbock, A. Visintin, R. W. Finberg, A. Tarakhovsky, S. N. Vogel, Y. Belkaid, E. A. Kurt-Jones, and C. L. Karp. 2005. Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat. Immunol. 6: 571-578.
27. Elson, G., I. Dunn-Siegrist, B. Daubeuf, and J. Pugin. 2007. Contribution of Toll-like receptors to the innate immune response to Gram-negative and Grampositive bacteria. Blood 109: 1574-1583.
28. Ruprecht, C. R., and A. Lanzavecchia. 2006. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur. J. Immunol. 36: 810-816.
29. Bohnhorst, J., T. Rasmussen, S. H. Moen, M. Flottum, L. Knudsen, M. Borset, T. Espevik, and A. Sundan. 2006. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 20: 1138-1144.
30. Teghanemt, A., R. L. Widstrom, T. L. Gioannini, and J. P. Weiss. 2008. Isolation of monomeric and dimeric secreted (s)MD-2: Endotoxin.sCD14 and toll-like receptor 4 ectodomain selectively react with the monomeric form of sMD-2. J. Biol. Chem. 283: 21881-21889.
31. Kennedy, M. N., G. E. Mullen, C. A. Leifer, C. Lee, A. Mazzoni, K. N. Dileepan, and D. M. Segal. 2004. A complex of soluble MD-2 and lipopolysaccharide serves as an activating ligand for Toll-like receptor 4. J. Biol. Chem. 279: 34698-34704.
32. Pajkrt, D., L. Camoglio, M. C. Tiel-van Buul, K. de Bruin, D. L. Cutler, M. B. Affrime, G. Rikken, T. van der Poll, J. W. ten Cate, and S. J. van Deventer. 1997. Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administration. J. Immunol. 158: 3971-3977.
33. de Waal Malefyt, R., J. Haanen, H. Spits, M. G. Roncarolo, A. te Velde, C. Figdor, K. Johnson, R. Kastelein, H. Yssel, and J. E. de Vries. 1991. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med 174: 915-924.
34. Voll, R. E., E. A. Roth, I. Girkontaite, H. Fehr, M. Herrmann, H. M. Lorenz, and J. R. Kalden. 1997. Histone-specific Th0 and Th1 clones derived from systemic lupus erythematosus patients induce double-stranded DNA antibody production. Arthritis Rheum. 40: 2162-2171.
35. Cassatella, M. A., L. Meda, S. Gasperini, F. Calzetti, and S. Bonora. 1994. Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. J. Exp. Med. 179: 1695-1699.
36. Hart, P. H., E. K. Hunt, C. S. Bonder, C. J. Watson, and J. J. Finlay-Jones. 1996. Regulation of surface and soluble TNF receptor expression on human monocytes and synovial fluid macrophages by IL-4 and IL-10. J. Immunol. 157: 3672-3680.
37. Gioannini, T. L., A. Teghanemt, D. Zhang, N. P. Coussens, W. Dockstader, S. Ramaswamy, and J. P. Weiss. 2004. Isolation of an endotoxin-MD-2 complex that produces Toll-like receptor 4-dependent cell activation at picomolar concentrations. Proc. Natl. Acad. Sci.USA 101: 4186-4191.
38. Visintin, A., K. A. Halmen, N. Khan, B. G. Monks, D. T. Golenbock, and E. Lien. 2006. MD-2 expression is not required for cell surface targeting of Toll-like receptor 4 (TLR4). J. Leukocyte Biol. 80: 1584-1592.
39. Schimke, J., J. Mathison, J. Morgiewicz, and R. J. Ulevitch. 1998. Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Proc. Natl. Acad. Sci. USA 95: 13875-13880.
40. Jacque, B., K. Stephan, I. Smirnova, B. Kim, D. Gilling, and A. Poltorak. 2006. Mice expressing high levels of soluble CD14 retain LPS in the circulation and are resistant to LPS-induced lethality. Eur. J. Immunol. 36: 3007-3016.
41. Grunwald, U., X. Fan, R. S. Jack, G. Workalemahu, A. Kallies, F. Stelter, and C. Schutt. 1996. Monocytes can phagocytose Gram-negative bacteria by a CD14-dependent mechanism. J. Immunol. 157: 4119-4125.
42. Peterson, P. K., G. Gekker, S. Hu, W. S. Sheng, W. R. Anderson, R. J. Ulevitch, P. S. Tobias, K. V. Gustafson, T. W. Molitor, and C. C. Chao. 1995. CD14 receptor-mediated uptake of nonopsonized Mycobacterium tuberculosis by human microglia. Infect. Immun. 63: 1598-1602.
43. Gregory, C. D., and A. Devitt. 1999. CD14 and apoptosis. Apoptosis 4: 11-20.